GI
NMRA icon

GAMMA Investing’s Neumora Therapeutics NMRA Stock Holding History

GAMMA Investing’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$298 Buy
+499
New +$691 ﹤0.01% 4248
2025
Q1 		– Sell
-16
Closed -$170 – 3856
2024
Q4 		$170 Sell
16
-37
-70% -$443 ﹤0.01% 3724
2024
Q3 		$700 Buy
53
+37
+231% +$432 ﹤0.01% 3341
2024
Q2 		$157 Buy
16
+7
+78% +$72 ﹤0.01% 3380
2024
Q1 		$124 Buy
+9
New +$146 ﹤0.01% 3275

Other funds holding NMRA

LPT
Legacy Private Trust Neenah, Wisconsin $1.83B AUM 13% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

GAMMA Investing's NMRA Position: Q3 2026 in Review

GAMMA Investing opened a new position in Neumora Therapeutics (NMRA) in Q3 2026: 499 shares worth $298. The stake represents ﹤0.01% of the portfolio and ranks #4248 among its holdings. This is a return to the name: GAMMA Investing previously reported a position in NMRA as recently as Q4 2024.

GAMMA Investing first reported a position in NMRA in Q1 2024 and has held it in 5 quarters since. The position peaked at $700 in Q3 2024. 6 funds tracked by Wall St. Rank hold NMRA as of Q3 2026.

  • GAMMA Investing held 499 shares of Neumora Therapeutics worth $298 as of Q3 2026.
  • Neumora Therapeutics was a new GAMMA Investing position in Q3 2026.
  • Neumora Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4248 holding.
  • GAMMA Investing first reported a position in Neumora Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • GAMMA Investing's Neumora Therapeutics position peaked at $700 in Q3 2024.
  • 6 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.